Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
Acta Clin Belg ; 74(5): 326-333, 2019 Oct.
Article in English | MEDLINE | ID: mdl-30235081

ABSTRACT

Background and objective: An accurate medication scheme may be a useful tool to improve medication safety in primary care. This study aimed to identify (1) pharmacists' alterations to nurse medication schemes and (2) potential improvements to the contribution of the community pharmacist to a shared medication scheme within a multidisciplinary collaboration. Dosing frequency, potentially incorrect moments of intake, drug-drug interactions and medication complexity (quantified by the Medication Regimen Complexity Index, MRCI) were investigated. Setting and method: Observational study in community dwelling older patients (≥70 years) with polypharmacy receiving home health care (i.e. medications being prepared and/or administered by home care nurses). Home care nurses provided the community pharmacist with the original medication scheme ('nurse medication scheme'), subsequently the community pharmacist generated a standardized 'pharmacist medication scheme' which was uploaded on an electronic health platform (Vitalink). The researcher recorded all pharmacists' alterations and looked for possible additional improvements ('researcher medication scheme'). Results: Pharmacists made 482 alterations to the nurse medication schemes of 31 patients. Most important alterations included adding indication (61%), generic or brand name (18%) and moment of intake (9%). Pharmacists did not reduce dosing frequency. MRCI scores (median [IQR]) significantly differed between pharmacist (38 [15]) and nurse medication schemes (32 [11]) (p < 0.001) and between nurse (32 [11]) and researcher medication schemes (40 [15]) (p < 0.001). Conclusion: Alterations made by the community pharmacists enable more complete and accurate medication schemes; however, there is room for improvement in optimizing the patient's medication scheme in a multidisciplinary collaboration.


Subject(s)
Community Pharmacy Services/organization & administration , Delivery of Health Care/organization & administration , Home Health Nursing/organization & administration , Polypharmacy , Professional Role , Aged , Aged, 80 and over , Clinical Protocols , Cross-Sectional Studies , Delivery of Health Care/methods , Female , Humans , Independent Living , Male , Patient Care Team , Pharmacists
2.
Rev. cienc. med. Pinar Rio ; 17(3): 92-101, mayo-jun. 2013.
Article in Spanish | LILACS | ID: lil-739913

ABSTRACT

Introducción: la diabetes mellitus en la población geriátrica es una afección crónica muy prevalente, que puede interaccionar o ser causa de producción de diversos síndromes geriátricos. Objetivo: caracterizar el comportamiento clínico epidemiológico de la diabetes mellitus en la tercera edad. Material y método: se realizó un estudio descriptivo, transversal y prospectivo, del adulto mayor en el policlínico "Isabel Rubio, del Consejo Popular San Diego de los Baños", municipio Los Palacios, durante el período comprendido entre enero y julio de 2011. El universo de estudio quedó conformado por los 198 gerontes dispensarizados como diabéticos en las historias clínicas familiares y la muestra estuvo integrada por 103 adultos mayores, escogidos aleatoriamente. Se aplicó la estadística descriptiva y ji cuadrado. Resultados: prevaleció la diabetes mellitus tipo 2 en ancianos de 60 a 69 años del sexo femenino (P>0,05). La combinación de dieta más hipoglucemiante oral resultó el esquema más empleado por los gerontes; el 85,2 % presentaba adherencia al tratamiento. El 39,0 % de los adultos mayores diabéticos tenían un control glicémico ideal. Conclusiones: predominó la diabetes mellitus tipo 2, grupo etáreo de 60 69 años en el género femenino. Más de 2/3 de los ancianos empleaban tratamiento farmacológico, la dieta más hipoglucemiante oral resultó el esquema terapéutico más empleado. La mayoría de los seniles presentaba adherencia a la terapia medicamentosa y más de la » parte de los diabéticos añosos presentaron control metabólico ideal.


Introduction: diabetes mellitus is a chronic and very prevalent disease in geriatric population, which can interact or be a cause of different syndromes in old ages. Objective: to characterize clinical-epidemiological behavior of diabetes mellitus in the elderly. Material and method: a descriptive, cross-sectional and prospective study was conducted at “Isabel Rubio” outpatient clinic belonging to the Popular Council of San Diego de los Baños, Los Palacios municipality during January-July 2011. The study included a target group of 198 diabetic old people diagnosed in their family clinical records and the sample was comprised of 103 old people chosen at random. Descriptive statistics and chi square test were applied. Results: diabetes mellitus type 2 prevailed in the elderly from 60 to 69 years old, and in female sex (P>0,05). The combination of diet plus oral hypoglycemic medications was the most used scheme; 85,2% followed the treatment correctly, 39,0% of the elderly had an ideal control of glycemia levels. Conclusions: diabetes mellitus type 2 prevailed in ages from 60 to 69 and in female sex. More than ¾ of the elderly underwent pharmacological treatment, diet plus oral hypoglycemic medications resulted in the most used therapeutic scheme. The majority of the old people followed a medication therapy and more than » of the diabetic old people presented an ideal metabolic control.

3.
China Pharmacy ; (12)2001.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-525121

ABSTRACT

OBJECTIVE:TO evaluate the economic effectiveness of the8medication schemes for preventing postoperation infections of cholecystitis and cholelithiasis.METHODS:The principle of pharmacoeconomics was adopted in the cost-effec-tiveness analysis of8medication schemes,ampicillin+amikacin+metroidazole(A),ampicloxacillin+metroidazole(B),lev-ofloxacin+metroidazole(C),cefoperazone/sulbactam+metroidazole(D),ceftazidime+metroidazole(E),piperacillin/tazobac-tam+metroidazole(F),ceftriaxone+metroidazole(G),cefotaxim/sulbactam+metroidazole(H).RESULTS:The costs for A,B,C,D,E,F,G and H schemes were72.75,497.75,339.75,392.75,1213.95,931.75,315.75and1409.75yuan respec-tively,with scheme A the lowest in cost;No significant differences were found in effectiveness among the8schemes.CON-CLUSION:Scheme A is superior to the others.

SELECTION OF CITATIONS
SEARCH DETAIL
...